Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy

Helicobacter

Volumn 15, Issue 4, 2010, Pages 265-272

  Kuo, Chao Hung ^a,b,c   Wang, Sophie S W ^b   Hsu, Wen Hung ^a   Kuo, Fu Chen ^d   Weng, Bi Chuang ^b   Li, Chia Jung ^b   Hsu, Ping I ^e   Chen, Angela ^f   Hung, Wen Chun ^f   Yang, Yuan Chieh ^b   Wang, Wen Ming ^a,b,c   Wu, Deng Chyang ^b,c,f  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

CYP2C19 genotype; Helicobacter pylori; quadruple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; RABEPRAZOLE; TETRACYCLINE; UREASE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; PROTON PUMP INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENUM ULCER; ERADICATION THERAPY; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH BIOPSY; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BREATH TEST; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

HELICOBACTER PYLORI;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; YOUNG ADULT;

EID: 77954825680     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00761.x     Document Type: Article

References (37)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
2. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 180.
3. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005 10 (Suppl 1 40 6.
4. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999 159 : 1562 1566.
5. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002 16 : 1269 1275.
6. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000 19 : 538 541.
7. Wang WH, Wong BC, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000 14 : 901 910.
8. Kirsch C, Morgner A, Miehlke S. Relevance of cytochrome P450 polymorphisms in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Curr Pharmacogenomics 2006 4 : 47 56.
9. Spengler G, Molnar A, Klausz G, Mandi Y, Kawase M, Motohashi N, Molnar J. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori. Int J Antimicrob Agents 2004 23 : 631 633.
10. Figura N, Crabtree JE, Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997 39 : 585 590.
11. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005 20 : 153 167.
12. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006 101 : 1467 1475.
13. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997 272 : 22438 22446.
14. Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000 44 : 3069 3073.
15. Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995 18 : 1053 1056.
16. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007 41 (Suppl 2 S226 42.
17. Wu IC, Ke HL, Lo YC, Yang YC, Chuang CH, Yu FJ, Lee YC, Jan CM, Wang WM, Wu DC. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 2003 50 : 1761 1765.
18. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 2002 97 : 2231 2238.
19. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 : 594 598. (Pubitemid 24334747)
20. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 15422.
21. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003 18 : 791 797.
22. Cheng HC, Chang WL, Chen WY, Yang HB, Wu JJ, Sheu BS. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007 12 : 359 363.
23. Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006 15 : 995 1016.
24. Miwa H, Nagahara A, Kurosawa A, Ohkusa T, Ohkura R, Hojo M, Enomoto N, Sato N. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003 17 : 1545 1551. (Pubitemid 36831446)
25. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 421 427.
26. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000 56 : 665 670.
27. Dent J. Review article: pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 2003 17 (Suppl 1 5 9.
28. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005 100 : 2387 2392.
29. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004 38 : 503 506.
30. Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, Wu JJ. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005 21 : 283 288.
31. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004 95 : 2 8.
32. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
33. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999 13 (Suppl 3 3 10.
34. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002 17 : 748 753.
35. Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001 15 : 793 803.
36. Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003 23 : 711 719.
37. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995 58 : 143 154.